Pages that link to "Q39933622"

The following pages link to Deletions of CDKN2C in multiple myeloma: biological and clinical implications (Q39933622):

Displaying 47 items.

• Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome (Q33737846) (← links)
• Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. (Q34223730) (← links)
• Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies (Q34272540) (← links)
• Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma (Q34296442) (← links)
• Identification of genomic alterations in pancreatic cancer using array-based comparative genomic hybridization (Q34682133) (← links)
• Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors (Q34707321) (← links)
• Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway (Q34918053) (← links)
• Expression profile of telomere-associated genes in multiple myeloma. (Q35370390) (← links)
• Single-molecule analysis reveals widespread structural variation in multiple myeloma. (Q35796097) (← links)
• Gender disparities in the tumor genetics and clinical outcome of multiple myeloma (Q35984694) (← links)
• Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. (Q36141851) (← links)
• A Conserved Gammaherpesvirus Cyclin Specifically Bypasses Host p18(INK4c) To Promote Reactivation from Latency. (Q36208092) (← links)
• Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach (Q36779423) (← links)
• Cyclin-dependent kinase inhibitor Cdkn2c regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus Sle2c1 (Q37176288) (← links)
• Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case (Q37246775) (← links)
• The genetic architecture of multiple myeloma (Q37718836) (← links)
• Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker (Q37744796) (← links)
• Clinical impact of chromosomal aberrations in multiple myeloma (Q37821077) (← links)
• Genomic stratification of multiple myeloma treated with novel agents (Q37913346) (← links)
• Multiple Myeloma: Current Perspectives (Q37961260) (← links)
• The genetic architecture of multiple myeloma. (Q38001913) (← links)
• Understanding the molecular biology of myeloma and its therapeutic implications (Q38065305) (← links)
• Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice (Q38165722) (← links)
• Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma (Q38348173) (← links)
• Contribution of B-1a cells to systemic lupus erythematosus in the NZM2410 mouse model (Q38366479) (← links)
• Identification of novel targets for multiple myeloma through integrative approach with Monte Carlo cross-validation analysis (Q38601323) (← links)
• Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy (Q38617375) (← links)
• Repression of CDKN2C caused by PML/RARα binding promotes the proliferation and differentiation block in acute promyelocytic leukemia (Q38728895) (← links)
• Genomic Aberrations in Multiple Myeloma (Q38970573) (← links)
• Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis. (Q39280199) (← links)
• Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders (Q39280908) (← links)
• Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable? (Q39788992) (← links)
• p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma (Q40382947) (← links)
• Understanding the multiple biological aspects leading to myeloma (Q42385107) (← links)
• Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation. (Q42509342) (← links)
• Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone (Q42867447) (← links)
• Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. (Q43989451) (← links)
• Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma (Q45219012) (← links)
• Reduced expression of ELAVL4 in male meningioma patients. (Q45399334) (← links)
• The therapeutic potential of cell cycle targeting in multiple myeloma (Q47203904) (← links)
• Evolutionary biology of high-risk multiple myeloma (Q47913337) (← links)
• Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma (Q50078440) (← links)
• Complete genomic landscape of a recurring sporadic parathyroid carcinoma (Q51042797) (← links)
• SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status (Q59602388) (← links)
• Genomic Aberrations and Survival of Patients with Light-Chain-Only Multiple Myeloma Undergoing Autologous Stem Cell Transplantation (Q84318275) (← links)
• Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma (Q86453803) (← links)
• Kinome expression profiling to target new therapeutic avenues in multiple myeloma (Q91753666) (← links)